Orsenix Eyes Opportunity For Oral Arsenic Leukemia Therapy
Executive Summary
Teva's Trisenox, an IV formulation of arsenic trioxide, was recently approved by the FDA as a first-line treatment for acute promyelocytic leukemia but Incyte founder Kris Vaddi's Orsenix believes its Phase III-ready oral version will take over the market.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.